Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Carboplatin 6amivantamab 4Pemetrexed 4osimertinib 3lazertinib 3Specimen Handling 3Prednisone 3Nivolumab 3Ado-Trastuzumab Emtansine 3trastuzumab deruxtecan 2talquetamab 2pertuzumab 2pembrolizumab 2niraparib 2ipatasertib 2eribulin 2erdafitinib 2entrectinib 2belzutifan 2atezolizumab 2apalutamide 2alectinib 2acalabrutinib 2Vinorelbine 2Trastuzumab 2Sunitinib 2Rituximab 2Paclitaxel 2Midazolam 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × acalabrutinib × 30 days × Clear all
NCT02213926 2026-05-18

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Acerta Pharma BV

Phase 2 Active not recruiting
124 enrolled 10 charts 1 FDA
Lymphoid

Lymphoma, Mantle-Cell

NCT02970318 2026-05-11

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Acerta Pharma BV

Phase 3 Active not recruiting
310 enrolled 18 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡